The HHS and the FDA have been ordered by US District Judge John Bates to restore the webpages on diversity following the court’s ruling.

Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

The China NMPA's CDE has granted approval to the IND application of InnoCare Pharma to initiate the trial of ICP-B794.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.